Different impacts of granulocyte colony-stimulating factor administration on allogeneic hematopoietic cell transplant outcomes for adult acute myeloid leukemia according to graft type.

Autor: Konuma T; Department of Hematology/Oncology, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan., Kameda K; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan., Morita K; Division of Hematology, Jichi Medical University, Shimotsuke, Japan., Kondo T; Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan., Kimura F; Division of Hematology, Department of Internal Medicine, National Defense Medical College, Tokorozawa, Japan., Nakasone H; Division of Hematology, Jichi Medical University Saitama Medical Center, Saitama, Japan.; Division of Stem Cell Regulation, Center for Molecular Medicine, Jichi Medical University, Shimotsuke, Japan., Ouchi F; Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan., Uchida N; Department of Hematology, Toranomon Hospital, Tokyo, Japan., Tanaka M; Department of Hematology, Kanagawa Cancer Center, Yokohama, Japan., Nishida T; Department of Hematology, Japanese Red Cross Aichi Medical Center Nagoya Daiichi Hospital, Nagoya, Japan., Fukuda T; Department of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan., Hasegawa Y; Department of Hematology, Hokkaido University Hospital, Sapporo, Japan., Sakata-Yanagimoto M; Department of Hematology, University of Tsukuba Hospital, Tsukuba, Japan., Onizuka M; Department of Hematology and Oncology, Tokai University School of Medicine, Isehara, Japan., Sawa M; Department of Hematology and Oncology, Anjo Kosei Hospital, Anjo, Japan., Ota S; Department of Hematology, Sapporo Hokuyu Hospital, Sapporo, Japan., Asada N; Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan., Fujiwara SI; Division of Hematology, Jichi Medical University, Shimotsuke, Japan., Yoshihara S; Department of Hematology, Hyogo Medical University Hospital, Nishinomiya, Japan., Ishimaru F; Technical Department, Japanese Red Cross Society Blood Service Headquarters, Tokyo, Japan., Yoshimitsu M; Department of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan., Kanda Y; Division of Hematology, Jichi Medical University, Shimotsuke, Japan., Ohbiki M; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan.; Department of Hematology and Oncology, Nagoya University Graduate School of Medicine, Nagoya, Japan., Atsuta Y; Japanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.; Department of Registry Science for Transplant and Cellular Therapy, Aichi Medical University School of Medicine, Nagakute, Japan., Yanada M; Department of Hematology and Oncology, Nagoya City University East Medical Center, Nagoya, Japan.
Jazyk: angličtina
Zdroj: American journal of hematology [Am J Hematol] 2024 Nov 20. Date of Electronic Publication: 2024 Nov 20.
DOI: 10.1002/ajh.27521
Abstrakt: We retrospectively evaluated the impacts of using granulocyte colony-stimulating factor (G-CSF) and its timing on posttransplant outcomes for 9766 adults with acute myeloid leukemia (AML) between 2013 and 2022 using a Japanese database. We separately evaluated three distinct cohorts based on graft type: 3248 received bone marrow transplantation (BMT), 3066 received peripheral blood stem cell transplantation (PBSCT), and 3452 received single-unit cord blood transplantation (CBT). Multivariate analysis showed that G-CSF administration significantly accelerated neutrophil recovery after BMT, PBSCT, and CBT. However, it was associated with a higher risk of grades II-IV acute graft-versus-host disease (GVHD) across all graft types. Moreover, an increased incidence of overall chronic GVHD was observed with G-CSF administration in BMT and CBT patients, but not in PBSCT patients. G-CSF administration significantly improved overall survival (OS) and leukemia-free survival (LFS) only following CBT. Regarding the timing of G-CSF, in comparison with late initiation of G-CSF (Days 5-10), early initiation (Days 0-4) did not provide benefits for hematopoietic recovery regardless of graft type. In contrast, late initiation was significantly associated with a lower risk of grades II-IV acute GVHD and better OS and LFS in CBT patients. These data demonstrated that G-CSF administration accelerated neutrophil recovery and increased the risk of grades II-IV acute GVHD across all graft types, but significantly improved survival outcomes but only following CBT. Therefore, routine use of G-CSF should be considered for CBT in adult patients with AML.
(© 2024 The Author(s). American Journal of Hematology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: